(NASDAQ: VERU) Veru's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.15%.
Veru's earnings in 2026 is -$13,608,554.On average, 4 Wall Street analysts forecast VERU's earnings for 2026 to be -$17,652,196, with the lowest VERU earnings forecast at -$17,878,966, and the highest VERU earnings forecast at -$17,186,723. On average, 4 Wall Street analysts forecast VERU's earnings for 2027 to be -$17,130,457, with the lowest VERU earnings forecast at -$18,881,524, and the highest VERU earnings forecast at -$15,038,382.
In 2028, VERU is forecast to generate -$11,478,275 in earnings, with the lowest earnings forecast at -$14,202,917 and the highest earnings forecast at -$8,414,333.